|
Aug 5
|
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025
|
|
Jul 17
|
AEMD: No SAEs in Cohort 1 Post-Hemopurifier Treatment; Progressing Trial to Cohort 2
|
|
Jul 15
|
Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort
|
|
Jul 2
|
AEMD: Progressing & Expanding Clinical & Pre-Clinical Activities in Cost Efficient Manner
|
|
Jun 26
|
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
|
|
Jun 20
|
Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025
|
|
Jun 18
|
Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial
|
|
Jun 16
|
Presenting on Emerging Growth Conference 83 Day 1 on June 17; Register to live stream
|
|
Jun 12
|
AEMD: Virtual Meeting With Management, Upcoming Presentation of Data in Long Covid
|
|
Jun 9
|
Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
|
|
Oct 9
|
Aethlon Medical Inc (AEMD) Q1 2025 Earnings Call Highlights: Strategic Cost Management and ...
|
|
Oct 8
|
Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit
|
|
Sep 20
|
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
|
|
Sep 19
|
Immunotherapy Clinical Trials - A New Approach to Treating Cancer
|
|
Sep 19
|
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
|
|
Sep 17
|
Aethlon Medical to Present at Virtual Investor Conferences in September
|
|
Sep 17
|
Innovation Driving Cancer's Solid Tumors Market
|
|
Sep 16
|
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
|
|
Sep 16
|
Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial
|
|
Aug 27
|
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys
|